Publisher： Bentham Science Publishers
E-ISSN： 1875-6557|6|2|124-133
ISSN： 1573-403X
Source： Current Cardiology Reviews, Vol.6, Iss.2, 2010-05, pp. : 124-133
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The emergence of new platforms for the discovery of innovative therapeutics has provided a means for diagnosing cardiac disease in its early stages. Taking into consideration the global health burden of cardiac disease, clinicians require innovations in medical diagnostics that can be used for risk stratification. Proteomic based studies offer an avenue for the discovery of proteins that are differentially regulated during disease; such proteins could serve as novel biomarkers of the disease state. For instance, in clinical practice, the abundance of such biomarkers in blood could be correlated with the severity of the disease state. As such, early detection of biomarkers would enable an improvement in patient prognosis. In this review, we outline advancements in various proteomic platforms used to study the disease proteome and their applications to the field of clinical medicine. Specifically, we highlight the contributions of proteomicbased profiling experiments to the analysis of cardiovascular diseases.
Related content
What We Have Learned about Cachexia in Gastrointestinal Cancer
Digestive Diseases, Vol. 21, Iss. 3, 2003-10 ,pp. :
Access to resources
Recommend
What We have Learned about Pain from Rodent Models of Arthritis?
Current Rheumatology Reviews, Vol. 6, Iss. 3, 2010-08 ,pp. :
Pain management today—what have we learned?
Clinical Rheumatology, Vol. 25, Iss. 1, 2006-07 ,pp. :
What we have learned from risk charts?
Future Cardiology, Vol. 6, Iss. 3, 2010-05 ,pp. :